Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A patient-level calibration framework for evaluating surveillance strategies: a case study of mammographic follow-up after early breast cancer|
|Citation:||Asia-Pacific Journal Of Clinical Oncology, 2014 / vol.10, iss.Suppl. 8, pp.95|
|Conference Name:||COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress (02 Dec 2014 - 04 Dec 2014 : Melbourne, Vic.)|
|Taryn Bessen, Jonathon Karnon|
|Abstract:||Objective: Currently all women who have completed their primary treatment for early breast cancer are invited to receive routine annual mammography. There is no randomised controlled trial evidence to support this schedule, and model-based analysis is required. This paper describes a novel data collection and model calibration process to analyse the costeffectiveness of alternative follow-up schedules for early breast cancer survivors. Methods: A discrete event simulation model describes the progression of early breast cancer after completion of primary treatment, representing impalpable and palpable recurrence and the detection of impalpable disease via follow-up mammography. Retrospective data from the South Australian cancer registry, and clinical and administrative hospital databases were linked for 407 postmenopausal women diagnosed with moderate prognosis early breast cancer from 2000-2008. These data formed the basis of a patient-level probabilistic calibration process. Results: For 50-69 year old survivors, annual follow-up for 5 years, with 2 yearly visits thereafter appears to be cost-effective. For women aged 70-79 years at diagnosis, a surveillance schedule similar to general population screening (2 yearly) appears to be most cost-effective if high rates of adherence can be maintained. Conclusions: This study had demonstrated the potential value of combining linked, retrospective data and decision analytic modelling to provide estimates of costs and health outcomes that are sufficiently robust to inform cancer clinical guidelines and individual patient decisions regarding appropriate follow-up schedules|
|Rights:||© 2014 The Authors. Asia-Pacific Journal of Clinical Oncology © 2014 Wiley Publishing Asia Pty Ltd|
|Appears in Collections:||Public Health publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.